Active, not recruitingPhase 2NCT04081220

Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

Studying Essential thrombocythemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The University of Texas Health Science Center at San Antonio
Principal Investigator
Zohra Nooruddin, MD
Mays Cancer Center
Intervention
IMG-7289(drug)
Enrollment
9 enrolled
Eligibility
18 years · All sexes
Timeline
2020 – 2026

Study locations (1)

Collaborators

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04081220 on ClinicalTrials.gov

Other trials for Essential thrombocythemia

Additional recruiting or active studies for the same condition.

See all trials for Essential thrombocythemia →

← Back to all trials